SCHEMBL25756752

SCHEMBL25756752

CCn1ccc2c(c(NC(=O)OC(C)(C)C)cn2CC(F)(F)F)c1=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.40
P2RX7 Q99572 1/20 0.35
P2RX3 P56373 1/20 0.34
ELANE P08246 3/20 0.33
RXFP1 Q9HBX9 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
KCNQ4 P56696 3/20 0.32
KCNQ5 Q9NR82 3/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
NR4A2 P43354 1/20 0.32
PDE10A Q9Y233 1/20 0.32
BACE1 P56817 1/20 0.32
BRD4 O60885 1/20 0.32
ACSS2 Q9NR19 1/20 0.32
CYP17A1 P05093 2/20 0.31
RORC P51449 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30895065 0.87 CNR2 (0.38) CNR2P2RX7P2RX3ELANERXFP1
SCHEMBL25756040 0.86 CNR2 (0.42) CNR2P2RX7ELANEKDM4EALDH1A1
SCHEMBL25670769 0.85 CNR2 (0.42) CNR2P2RX7P2RX3ELANERXFP1
SCHEMBL27199568 0.85 PTGDR2 (0.35) KDM4EALDH1A1NR4A2PDE10ABRD4
SCHEMBL30895028 0.81 CNR2 (0.38) CNR2P2RX7P2RX3ELANE
SCHEMBL25757055 0.78 OPRM1 (0.34) CNR2ELANEBACE1BRD4ACSS2
SCHEMBL25118297 0.76 KDM4E (0.50) CNR2ELANERXFP1KDM4EALDH1A1
SCHEMBL30895118 0.76 CNR2 (0.37) CNR2ELANEKDM4EALDH1A1LMNA
SCHEMBL25671109 0.75 CNR2 (0.39) CNR2P2RX7P2RX3ELANERXFP1
SCHEMBL25752652 0.75 CNR2 (0.39) CNR2P2RX7ELANERXFP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 CNR2 3169/4885P2RX7 3505/4885P2RX3 3878/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 CNR2 3169/4885P2RX7 3505/4885P2RX3 3878/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 CNR2 3169/4885P2RX7 3505/4885P2RX3 3878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.